US2011003971A1PendingUtilityA1

Modulators and modulation of the interaction between rgm and neogenin

51
Assignee: ABBOTT LABPriority: Jun 26, 2002Filed: Apr 12, 2010Published: Jan 6, 2011
Est. expiryJun 26, 2022(expired)· nominal 20-yr term from priority
Inventors:Stephen M. StrittmatterBernhard Mueller
C07K 14/475G01N 33/566G01N 2500/00G01N 2500/02C07K 14/71C07K 14/705C07K 16/28A61K 2039/505Y10S530/839G01N 33/53G01N 33/68G01N 2500/10
51
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

This invention relates to drug screening using mammalian repulsive guidance molecules and mammalian Neogenin. In addition, the invention provides for methods of preventing, alleviating or treating various disorders of the nervous system, angiogenic disorders or disorders of the cardio-vascular system and malignancies of different etiology by disrupting the interaction between RGM and Neogenin.

Claims

exact text as granted — not AI-modified
1 .- 13 . (canceled) 
     
     
         14 . An antibody preparation which specifically inhibits the interaction of a Neogenin protein and an RGM protein. 
     
     
         15 - 17 . (canceled)

Join the waitlist — get patent alerts

Track US2011003971A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.